Peter Nightingale - Biotron Company Secretary
BITRF Stock | USD 0.06 0.00 0.00% |
Executive
Mr. Peter James Nightingale was Company Secretary of Biotron Ltd since February 23, 1999. Mr. Nightingale graduated with a Bachelor of Economics degree from the University of Sydney and is a member of the Institute of Chartered Accountants in Australia. He has worked as achartered accountant in both Australia and the USA. As a director or company secretary Mr. Nightingale has, for more than 25 years, been responsible for the financial control, administration, secretarial and inhouse legal functions of a number of private and public listed companies in Australia, the USA and Europe including Bolnisi Gold N.L., Callabonna Uranium Limited, Mogul Mining N.L., Pangea Resources Limited, Perseverance Corporation Limited, Sumatra Copper Gold plc, Timberline Minerals, Inc. and Valdora Minerals N.L. Mr. Nightingale is currently a director of ASX listed Augur Resources Ltd, Cockatoo Coal Limited and Planet Gas Limited and unlisted public companies Equus Resources Limited and Nickel Mines Limited. since 1999.
Tenure | 25 years |
Phone | 61 2 9300 3344 |
Web | https://www.biotron.com.au |
Biotron Management Efficiency
The company has return on total asset (ROA) of (0.5574) % which means that it has lost $0.5574 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1224) %, meaning that it generated substantial loss on money invested by shareholders. Biotron's management efficiency ratios could be used to measure how well Biotron manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Shahe Garabedian | TRACON Pharmaceuticals | N/A | |
Ya Huang | TRACON Pharmaceuticals | N/A | |
John Brozek | Genfit | 47 | |
Emilie Desodt | Genfit | 41 | |
David MS | Ikena Oncology | N/A | |
Ronald Shazer | TRACON Pharmaceuticals | 47 | |
Joseph Cappello | Genelux Common | 67 | |
Nicole Esq | HCW Biologics | N/A | |
Samantha Vuksanic | Ikena Oncology | N/A | |
Thomas Dalton | Cingulate | N/A | |
Patrick MBA | Protara Therapeutics | 56 | |
Yong Yu | Genelux Common | 52 | |
Bob Lally | Ikena Oncology | N/A | |
Philippe Moons | Genfit | N/A | |
Justine OMalley | Protara Therapeutics | N/A | |
Alexander Constan | Ikena Oncology | N/A | |
Valerie Morisset | Eliem Therapeutics | 54 | |
Meriam Kabbaj | Genfit | 50 | |
Pr MD | Genelux Common | 78 | |
Valdas Jurkauskas | Ikena Oncology | N/A | |
Sean JD | Genelux Common | 54 |
Management Performance
Return On Equity | -1.12 | |||
Return On Asset | -0.56 |
Biotron Limited Leadership Team
Elected by the shareholders, the Biotron's board of directors comprises two types of representatives: Biotron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotron. The board's role is to monitor Biotron's management team and ensure that shareholders' interests are well served. Biotron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotron's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Thomas, Independent Non-Executive Director | ||
BSc GCertAppFin, MD Director | ||
Peter Nightingale, Company Secretary | ||
Michael Hoy, Independent Non-Executive Chairman of the Board | ||
Michelle Miller, CEO, Managing Director, Executive Director | ||
Stephen Locarnini, Director | ||
CA BEcon, Company Sec | ||
Denis Wade, Independent Non-Executive Director | ||
Stephen MD, Chief Officer | ||
Susan Pond, Independent Non-Executive Director |
Biotron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Biotron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.12 | |||
Return On Asset | -0.56 | |||
Profit Margin | (1.78) % | |||
Operating Margin | (1.78) % | |||
Current Valuation | 15.31 M | |||
Shares Outstanding | 901.94 M | |||
Shares Owned By Insiders | 14.13 % | |||
Price To Earning | (3.04) X | |||
Price To Book | 23.61 X | |||
Price To Sales | 11.17 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biotron in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biotron's short interest history, or implied volatility extrapolated from Biotron options trading.
Pair Trading with Biotron
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biotron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotron will appreciate offsetting losses from the drop in the long position's value.Moving against Biotron Pink Sheet
0.76 | WF | Woori Financial Group Financial Report 21st of May 2024 | PairCorr |
0.63 | SHG | Shinhan Financial | PairCorr |
0.5 | NONOF | Novo Nordisk AS Earnings Call Today | PairCorr |
0.48 | NVO | Novo Nordisk AS | PairCorr |
0.48 | KB | KB Financial Group Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Biotron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biotron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biotron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biotron Limited to buy it.
The correlation of Biotron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biotron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biotron Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biotron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biotron Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Biotron Pink Sheet analysis
When running Biotron's price analysis, check to measure Biotron's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotron is operating at the current time. Most of Biotron's value examination focuses on studying past and present price action to predict the probability of Biotron's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotron's price. Additionally, you may evaluate how the addition of Biotron to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |